Make No Mistake: Patentee Held to Terminal Disclaimer Despite Unwitting Reliance on Patent Office Error

July 23, 2024

Reading Time : 2 min

A court in the Western District of Oklahoma dismissed a complaint as to one of the asserted patents where the patent included a terminal disclaimer stating that the patent would be enforceable only as long as it was co-owned with a reference patent that the PTO had misidentified. The court relied on the public notice function of the patent system to hold the plaintiff to the exact language in its terminal disclaimer, and held that the asserted patent was unenforceable from the moment it issued because it and the reference patent were never co-owned.

During prosecution, the PTO rejected the claims of the asserted patent on obviousness-type double patenting grounds over the ’267 patent. But the ’267 patent was directed to completely different subject matter and owned by a different entity. Nonetheless, plaintiff overcame that rejection by filing a terminal disclaimer stating that the asserted patent and the ’267 patent were commonly owned by plaintiff and agreeing that the asserted patent would be enforceable only during such period that it and the ’267 patent were commonly owned. But plaintiff never owned the ’267 Patent. It did own the ’268 patent, which was in the same family as the asserted patent, but not mentioned in the office action. Several years after the PTO issued the asserted patent, plaintiff petitioned to withdraw the ’267 disclaimer and replace it with a new terminal disclaimer based on the ’268 patent. The PTO denied the request to withdraw but allowed plaintiff to file a new terminal disclaimer with respect to the ’268 patent.

In its motion to dismiss, defendant argued that the terms of the terminal disclaimer were clear: the asserted patent would be enforceable only while it and the ’267 patent were commonly owned. And because the two patents were never commonly owned, the asserted patent was never enforceable. Plaintiff explained that the ’267 terminal disclaimer was ineffective because it was disconnected from the purpose of a terminal disclaimer—to resolve an obviousness-type double patenting issue. Plaintiff further argued that regulations bar a patent applicant from filing a terminal disclaimer to a patent that it does not commonly own. Finally, plaintiff argued that the mistake would be obvious to anyone reading the prosecution history of the patent.

The court acknowledged the dearth of opinions addressing an erroneous terminal disclaimer, but explained that the public is entitled to rely on the clear terms in a patentee’s terminal disclaimer.  Here, the patentee gave notice to the public that the asserted patent was unenforceable so long as it was commonly owned with the ’267 patent. The two patents were never commonly owned, and the court could not assume no member of the public ever relied on the ’267 patent disclaimer.  The court was not persuaded that the mistake was obvious because even the patentee itself did not notice the error for years. Because the ’267 disclaimer rendered the asserted patent unenforceable, the court granted defendant’s motion to dismiss.

Practice Tip: Patent applicants should carefully review both the PTO’s obviousness-type double patenting rejections and their own terminal disclaimers to ensure that there are no errors. The public notice function of the patent system could lead a court to strictly interpret a terminal disclaimer as it is written, even if it refers to a patent that the PTO had erroneously identified.

SIPCO, LLC v. Jasco Prods. Co., LLC, No. CIV-19-00709-PRW (W.D. Okla. May 29, 2024)

Share This Insight

Previous Entries

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.